Indivior Pharmaceuticals, Inc. INDV Business Segments — Cost of Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's business segments — cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's business segments — cost of sales?
- Indivior Pharmaceuticals, Inc. (INDV) reported business segments — cost of sales of $40M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's business segments — cost of sales changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's business segments — cost of sales decreased by 9.1% year-over-year, from $44M to $40M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's business segments — cost of sales?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's business segments — cost of sales has grown at a 17.7% compound annual growth rate (CAGR), from $151M to $246M.
- What does business segments — cost of sales mean?
- Includes the direct costs attributable to the production and distribution of the segment's pharmaceutical products. Monitoring this metric is essential for assessing manufacturing efficiency and the impact of input cost fluctuations on segment margins.